The company, which offers drug discovery and manufacturing services to pharma clients, has undertaken capacity expansion for custom synthesis. It plans to add 155 kilolitres of capacity to take the total to 425 kilolitres by the end of September 2025. For FY26, it expects 20% growth in revenue.
The company added 54 kilolitres of capacity in the June quarter and 76 kiloliters more will be commissioned by the end of 2025. It will also be adding 40 kilolitres in NeoAnthem, its subsidiary, by 2025-end.
The company’s two products which were in the filing stage received approval resulting in the commercial portfolio increasing to 12 from 10. This augurs well for its revenue growth.
In the June quarter, Anthem Biosciences’ revenue from operations jumped 59.5% year-on-year to ₹540.2 crore, while net profit surged by 64.8% to ₹135.8 crore. The growth in revenue was driven by commercialised molecules and larger quantity requirements from five or six clients.
Anthem said this drastic growth might not happen in every quarter and, hence, it has guided for an annual revenue growth of around 20%, based on the 10-year historical growth, which is about 22%.
AgenciesThe operating margin before depreciation and amortisation (Ebitda margin) dropped to 38.1% from 39.2% a year ago. This was largely due to a share-based compensation charge of about ₹4.4 crore during the quarter, which was not there in the previous year. When adjusted for this, the margin was steady year-on-year.The backward integration on one of the key molecules has been done and the company is no longer reliant on any external sources of supply. The benefits of this will be seen in the company’s gross margin for the coming quarters.
Further, obesity and diabetes controlling drug GLP-1 will be going off patent in multiple markets next year and Anthem has already supplied samples to its customers. It is working on developing the drug. This offers a potential growth opportunity.
as a Reliable and Trusted News Source